0000899243-19-022047.txt : 20190819 0000899243-19-022047.hdr.sgml : 20190819 20190819163547 ACCESSION NUMBER: 0000899243-19-022047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190815 FILED AS OF DATE: 20190819 DATE AS OF CHANGE: 20190819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: New Leaf Venture Management III, L.L.C. CENTRAL INDEX KEY: 0001625657 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 191036872 BUSINESS ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 646-871-6400 MAIL ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: New Leaf Ventures III, L.P. CENTRAL INDEX KEY: 0001625653 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 191036873 BUSINESS ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 646-871-6400 MAIL ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: New Leaf Biopharma Opportunities I, L.P. CENTRAL INDEX KEY: 0001625696 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 191036874 BUSINESS ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 646-871-6400 MAIL ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER NAME: FORMER CONFORMED NAME: New Leaf Growth Fund I, L.P. DATE OF NAME CHANGE: 20141117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: New Leaf Venture Associates III, L.P. CENTRAL INDEX KEY: 0001625656 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 191036875 BUSINESS ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 646-871-6400 MAIL ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: New Leaf BPO Associates I, L.P. CENTRAL INDEX KEY: 0001625693 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 191036876 BUSINESS ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 646-871-6400 MAIL ADDRESS: STREET 1: C/O NEW LEAF VENTURE PARTNERS STREET 2: 7 TIMES SQUARE, SUITE 3502 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER NAME: FORMER CONFORMED NAME: New Leaf Growth Associates I, L.P. DATE OF NAME CHANGE: 20141117 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-08-15 1 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001625657 New Leaf Venture Management III, L.L.C. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK NY 10170 0 0 1 0 0001625653 New Leaf Ventures III, L.P. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK NY 10170 0 0 1 0 0001625696 New Leaf Biopharma Opportunities I, L.P. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK NY 10170 0 0 1 0 0001625656 New Leaf Venture Associates III, L.P. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK NY 10170 0 0 1 0 0001625693 New Leaf BPO Associates I, L.P. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK NY 10170 0 0 1 0 Common Stock 2019-08-15 4 S 0 71550 36.0911 D 1886282 I See Footnote Common Stock 2019-08-16 4 S 0 69292 36.5433 D 1816990 I See Footnote Common Stock 2019-08-16 4 S 0 26108 37.0148 D 1790882 I See Footnote Common Stock 2019-08-15 4 S 0 78450 36.0911 D 2067858 I See Footnote Common Stock 2019-08-16 4 S 0 75974 36.5433 D 1991884 I See Footnote Common Stock 2019-08-16 4 S 0 28626 37.0148 D 1963258 I See Footnote The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. The reportable securities are owned directly by New Leaf Ventures III, L.P. ("NLV III"). New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. (Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. (Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. /s/ Craig Slutzkin, attorney-in-fact for New Leaf Ventures III, L.P. 2019-08-19 /s/ Craig Slutzkin, attorney-in-fact for New Leaf Biopharma Opportunities I, L.P. 2019-08-19 /s/ Craig Slutzkin, attorney-in-fact for New Leaf Venture Associates III, L.P. 2019-08-19 /s/ Craig Slutzkin, attorney-in-fact for New Leaf BPO Associates I, L.P. 2019-08-19 /s/ Craig Slutzkin, attorney-in-fact for New Leaf Venture Management III, L.L.C. 2019-08-19